Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) becomes resistant to Dolutegravir, one of the most effective, clinically used antiviral drugs for treating HIV.
Gprc5a identified as potential drug target for treating osteoporosis
Osteoporosis is a skeletal condition that leads to the weakening of bones, making them porous, fragile, and prone to breakage.
June 18, 2024